Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$166.15 USD
-0.92 (-0.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $166.16 +0.01 (0.01%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$166.15 USD
-0.92 (-0.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $166.16 +0.01 (0.01%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth C Momentum D VGM
Zacks News
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Q1 Earnings To Watch For
by Zacks Equity Research
Q1 Earnings To Watch For
Q1 Earnings Spigot Opens: JNJ, BAC, UNH & More
by Mark Vickery
This is the first "full week" of Q1 earnings season, though the influx of reports hitting the tape in the next few weeks to come will be even heavier.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
J&J (JNJ) Tops Q1 Earnings; Pharma Segment Drives Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019. Hikes 2019 guidance for operational sales and earnings growth. Shares up in pre-market trading.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 3.45% and 2.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
by Zacks Equity Research
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Banks Deliver and the Rally Continues
by David Borun
After an encouraging start to earnings season, stocks continue to rise.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Looking for a Growth Stock? 3 Reasons Why Johnson & Johnson (JNJ) is a Solid Choice
by Zacks Equity Research
Johnson & Johnson (JNJ) could produce exceptional returns because of its solid growth attributes.
Earnings Optimism Following Bank Results
by Sheraz Mian
If we aggregate these positive surprises to the entire S&P 500 index, then it is reasonable to envision a Q1 earnings growth pace that may not be negative, after all.
Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
by Zacks Equity Research
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
What's in Store for Dow ETF in Q1 Earnings?
by Sweta Killa
Let's delve into the Q1 earnings picture that will likely set up the movement of the Dow Jones ETF in the coming days.
Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
by Zacks Equity Research
Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Alkermes Reports Positive Data From Schizophrenia Study
by Zacks Equity Research
Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.
5 Stocks to Prepare for a Global Economic Slowdown
by Swarup Gupta
In such an event, demand for products and services generated by utilities, consumer staples and medical companies remain invariant.
Johnson & Johnson (JNJ) Stock Moves -0.47%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $135.50 in the latest trading session, marking a -0.47% move from the prior day.
Earnings Preview: Johnson & Johnson (JNJ) Q1 Earnings Expected to Decline
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
by Zacks Equity Research
Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
J&J Stock on an Uptrend This Year So Far: More Room to Run?
by Zacks Equity Research
J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.
Company News For Apr 8, 2019
by Zacks Equity Research
Companies In The News Are: BA, ABMD, TGI, C, JNJ